• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy.
Authors: Rivera-Caravaca JM, Esteve-Pastor MA, Camelo-Castillo A, Ramírez-Macías I, Lip GYH, Roldán V, Marín F Abstract INTRODUCTION: Oral anticoagulants (OAC) reduce stroke/systemic embolism and mortality risks in atrial fibrillation (AF). However, there is an inherent bleeding risk with OAC, where intracranial hemorrhage (ICH) is the most feared, disabling, and lethal complication of this therapy. Therefore, the optimal management of OAC-associated ICH is not well defined despite multiple suggested strategies. AREAS COVERED: In this review, the authors describe the severity and risk factors for OAC-associ...
Source: Expert Opinion on Pharmacotherapy - July 15, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Chronic Kidney Disease and Third-Generation P2Y12 Inhibitors Use in Patients With Acute Coronary Syndrome: Impact on the Prognosis at 1 Year.
In conclusion, the use of third-generation P2Y12 inhibitors among non-CKD patients was associated with better outcomes. CKD patients receiving third-generation P2Y12 inhibitors treatment showed no statistically significant lower mortality and thrombotic events. Bleeding risk was not increased with the use of third-generation P2Y12 inhibitors in either group of patients. PMID: 30207603 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Pharmacology - September 12, 2018 Category: Drugs & Pharmacology Authors: Tello-Montoliu A, Ruiz-Nodar JM, Esteve-Pastor MA, Véliz-Martínez A, Orenes-Piñero E, Macías-Villanego MJ, Lozano T, Carrillo-Alemán L, Vicente-Ibarra N, Pernias-Escrig V, Martínez-Martínez JG, Rivera-Caravaca JM, Marín F Tags: J Clin Pharmacol Source Type: research